-
Mashup Score: 0High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types - 4 month(s) ago
High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been fully demonstrated across all cancers.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
PURPOSE Nivolumab plus relatlimab and nivolumab plus ipilimumab have been approved for advanced melanoma on the basis of the phase II/III RELATIVITY-047 and phase III CheckMate 067 trials, respectively. As no head-to-head trial comparing these regimens exists, an indirect treatment comparison was conducted using patient-level data from each trial. METHODS Inverse probability of treatment weighting (IPTW) adjusted for baseline characteristic differences. Minimum follow-ups (RELATIVITY-047, 33 months; CheckMate 067, 36 months) were selected to best align assessments. Outcomes included progression-free survival (PFS), confirmed objective response rate (cORR), and melanoma-specific survival (MSS) per investigator; overall survival (OS); and treatment-related adverse events (TRAEs). A Cox regression model compared PFS, OS, and MSS. A logistic regression model compared cORRs. Subgroup analyses were exploratory. RESULTS After IPTW, key baseline characteristics were balanced for nivolumab plus
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data | Journal of Clinical Oncology https://t.co/Xq8JoueeLP
-
-
Mashup Score: 2Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials - 4 month(s) ago
CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet-
This remains an awesome paper! I wish they would do this for all modern cancer drugs! Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials | Science Translational Medicine https://t.co/xR3poLgaC6
-
-
Mashup Score: 6
Despite the interest from the scientific community and regulatory agencies, limited data are available on the association between health-related quality-of-life (QoL) results, outcome of efficacy and drug approvals.
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
Less than 40% of oncology trials leading to regulatory approval have reported an improvement in global QoL. @ESMO_Open https://t.co/9ULn1VO4DN
-
-
Mashup Score: 0Beginning at the End? Rethinking the Timing of Enrollment Into Early Phase Clinical Trials | JCO Oncology Practice - 5 month(s) ago
Patients with advanced unresectable malignancies and preserved performance status typically undergo several lines of standard-of-care (SOC) life-extending or palliative systemic therapies, with the goal of inducing disease control or remission. Per conventional wisdom, once a patient’s disease progresses through these SOC treatments and they have exhausted all other options, the y may ultimately be candidates for early phase clinical trials. In this vulnerable state, patients often decide to enroll in
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Worth thinking through: pros and cons. #MedEd #Oncology Beginning at the End? Rethinking the Timing of Enrollment Into Early Phase Clinical Trials | @JCOOP_ASCO https://t.co/g7WxVH9EAZ
-
-
Mashup Score: 0
Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Remember that ORR with CDk4+SERD = 10% https://t.co/331KPQxU8g So you would have to believe synergy of investigational compound, since little sign of independently better. A lesson in sticking to the plan?
-
-
Mashup Score: 0
Abstract. Background: In Arm 2 of the ongoing AMEERA-1 trial (NCT03284957), amcenestrant, an optimized oral SERD combined with the CDK4/6 inhibitor (CDK4/6i) palbociclib demonstrated favorable safety and encouraging antitumor activity among patients with endocrine-resistant ER+/HER2− advanced breast cancer in dose escalation (Part C) and dose expansion (Part D) (Chandarlapaty et al., ASCO 2021; abstract 1058). Here we report an update of safety, antitumor activity data, and progression-free survival (PFS), of amcenestrant 200 mg in combination with palbociclib. Analysis of genomic data, including modulation over time and correlation with clinical outcome, will also be presented. Methods: The trial enrolled postmenopausal women with ER+/HER2- locally-advanced or metastatic breast cancer with disease progression while on ≥ 6 months of prior endocrine therapy (ET) in the advanced setting, or who relapsed on adjuvant ET after the first 2 years of treatment or within 12 months of completing
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
P1/2: Part C+D formed the basis of p3 (same study as P1 above). At a data cutoff of May 30, 2021, Only available in abstract form https://t.co/D4SB97hwei
-
-
Mashup Score: 0AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer - 5 month(s) ago
Nature Communications – There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Anyone in #bcsm with insight into this clinical development plan? ✅P1: enrolled 2017 to 26 March 2020 https://t.co/fwBabxWNce ❌P2: enrolled 2019 to February 15, 2021 https://t.co/m3bH8TBL5C ❌P3: enrolled October 14, 2020 to December 2, 2021 https://t.co/aj4sEnwWy5
-
-
Mashup Score: 0
On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study, coded TroFuse-020, marked the 10th global phase 3 trial the New Jersey pharma has logged for its Kelun Biotech-partnered antibody-drug conjugate, sacituzumab tirumotecan, in about eight months.And Merck isn’t finished. “A bunch” of pivotal trials for the drug, also known as sac-TMT or MK-2870, are being devised behind closed doors at the company, Eliav Barr, M.D., chief medical officer at Merck Research Laboratories, said in a recent interview before the latest trial registration. | On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study marked the 10th global phase 3 trial that the New Jersey pharma has logged for its Kelun Biotech-partnered ADC, sacituzumab tirumotecan, in about eight months. And Merck isn’t finished.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
33 TROP2-ADC p3 trials??? On crowding in pharma, and how PTS trumps revenue potential. And how expected value is the focus, to the detriment of Value At Risk. https://t.co/Nt06OyL2m7
-
-
Mashup Score: 0Essay | Your Gen-Z Employee Isn’t Fooled by Your Compliment Sandwich - 5 month(s) ago
Sharing constructive criticism with the next generation requires an approach based on respect.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet-
“people will take even the most severe criticism well if it is clear that the feedback was motivated by an appreciation for their potential.” At the same time, if feedback is a gift, the recipient has to want to receive it. #meded https://t.co/38HT5eIJ6K
-
FDA approvals are not a surrogate for efficacy. Exhibit A in the tumor agnostic space: TMB-H https://t.co/J0cTQkSYQs https://t.co/4cS2dlhZlY